Patent Number: 8,722,622

Title: FGF21 conjugates and anti-diabetic uses thereof

Abstract: The present invention provides a FGF21 molecule covalently attached to the combining site of an antibody via a linker, wherein the linker is covalently attached to the side chain of a linking residue within FGF21. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.

Inventors: Das; Tapan Kanti (Ballwin, MO), Hodge; Tamara Shafer (Ballwin, MO), Ishino; Tetsuya (Boston, MA), Levin; Nancy Jane (Encinitas, CA), Palanki; Moorthy Sitharamaiah Suriyanarayana (Encinitas, CA), Parsons; Erin Kristen (University City, MO), Violand; Bernard Norman (Wildwood, MO)

Assignee: COVX Technologies Ireland, Limited

International Classification: A61K 38/18 (20060101); A61K 39/395 (20060101)

Expiration Date: 5/13/12018